Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study
- Authors: Golubenko E.O.1, Savelyeva M.I2, Sozaeva Z.A3, Poddubnaya I.V3, Korennaya V.V3
-
Affiliations:
- Center for Immunology and Reproduction
- Yaroslavl State Medical University
- ussian Medical Academy of Continuous Professional Education
- Issue: Vol 29, No 11/12 (2022)
- Pages: 118-126
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321114
- DOI: https://doi.org/10.18565/pharmateca.2022.11-12.118-126
- ID: 321114
Cite item
Abstract
Full Text
About the authors
Ekaterina O. Golubenko
Center for Immunology and Reproduction
Email: kate.golubenko@yandex.ru
Obstetrician-Gynecologist Moscow, Russia
M. I Savelyeva
Yaroslavl State Medical Universityaroslavl, Russia
Zh. A Sozaeva
ussian Medical Academy of Continuous Professional EducationMoscow, Russia
I. V Poddubnaya
ussian Medical Academy of Continuous Professional EducationMoscow, Russia
V. V Korennaya
ussian Medical Academy of Continuous Professional EducationMoscow, Russia
References
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020.CA Cancer J Clin. 2020;70:7-30.
- Huang B, Warner M., Gustafsson J.A. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418(Pt 3):240-44. doi: 10.1016/j.mce.2014.11.015.
- Rugo H.S., Rumble R.B., Macrae E., et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34(25):3069-103. Doi: 10.1200/ JCO.2016.67.1487.
- Sanchez-Spitman A.B., Swen J.J., Dezentje V.O., et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Exp Rev.Clin. Pharmacol. 2019;12:6, 523-36. doi: 10.1080/17512433.2019.1610390.
- Brauch H., Murdter T.E., Eichelbaum M, et al. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009;55(10):1770-82. Doi: 10.1373/ clinchem.2008.121756.
- Relling M.V, Klein T.E. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464-467. doi: 10.1038/clpt.2010.279.
- Saladores P., Murdter T., Eccles D., et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15(1):84-94. doi: 10.1038/tpj.2014.34.
- Schroth W., Goetz M.P, Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302 (13):1429-36. doi: 10.1001/jama.2009.1420.
- Sanchez-Spitman A., Dezentje V., Swen J., et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol. 2019;37(8):636-46. Doi: 10.1200/ JCO.18.00307.
- Binkhorst L., Mathijssen R.H., Jager A., van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 geno-typing. Cancer Treat Rev. 2015;41:289-99. Doi: 10.1016/j. ctrv.2015.01.002.
- Thompson A.M., Johnson A., Quinlan P., et al.Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125:279-87. doi: 10.1007/s1054 9-010-1139-x.
- Joffe H, Deckersbach T., Lin N.U., et al. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study. J Clin Endocrinol Metab. 2012; 97:3207-15. doi: 10.1210/jc.2012-1413.
- Suzanne D. Conzen, Lynn Henry N. Managing the side effects of tamoxifen and aromatase inhibitors. URL: https://www.uptodate.com/contents/managing-the-side-effects-of-tamoxifen-and-aromatase-inhibitors/print?search=tamoxifen
- Kedar R.P, Bourne T.H., Powles T.J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318. doi: 10.1016/s0140-6736(94)92466-x.
- Goetz M.P, Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312. doi: 10.1200/JC0.2005.03.3266.
- Sensorn I., Sukasem C., Sirachainan E., et al. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Onco Targets Ther. 2016;9:2121-29. Published online 2016 Apr 12. doi: 10.2147/OTT. S100905.
- Irvin W.J., Walko C.Mю, Weck K.E., et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(24):3232-39. doi: 10.1200/JCO.2010.31.4427.
- Schroth W., Goetz M.P, Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early-stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-36. Doi: 10.1001/ jama.2009.1420.
- Dean L. Tamoxifen therapy and CYP2D6 genotype. SourceMedical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-2014 Oct 7. PMID: 28520357.
- Mwinyi J., Vokinger K., Jetter A., et al. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol. 2014;73:1181-88. doi: 10.1007/s00280-014-2453-5.
- Swen J.J., Nijenhuis M., de Boer A., et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clinical pharmacology and therapeutics. 2011;89(5):662-73. doi: 10.1038/clpt.2011.34.
- Khan B.A., Robinson R., Fohner A.E., et al. Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People Clin Transl Sci. 2018;11(3):312-21. Doi: 10.1111/ cts.12542.
- Cronin-Fenton D.P., Damkier P. Tamoxifen and CYP2D6: A CONTROVERSY IN PHARMacogenetics. Adv Pharmacol. 2018;83:65-91. Doi: 10.1016/ bs.apha.2018.03.001.
- Carmen W.H. Chan, Bernard M.H. Law, Winnie K.W. So, et al. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 24 March 2020. doi: 10.1007/S00432-020-03206-W.